Home

Exelixis, Inc. - Common Stock (EXEL)

44.92
-0.48 (-1.06%)
NASDAQ · Last Trade: May 19th, 12:04 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close45.40
Open45.40
Bid44.90
Ask44.94
Day's Range44.80 - 46.22
52 Week Range20.14 - 48.85
Volume961,244
Market Cap14.15B
PE Ratio (TTM)20.42
EPS (TTM)2.2
Dividend & YieldN/A (N/A)
1 Month Average Volume3,446,219

Chart

About Exelixis, Inc. - Common Stock (EXEL)

Exelixis Inc is a biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company primarily engages in the discovery, development, and commercialization of small molecule drugs that target key pathways involved in cancer cell growth and survival. Through its research and clinical development programs, Exelixis aims to provide effective treatment options that improve patient outcomes and enhance the quality of life for individuals battling various forms of cancer. The company's commitment to oncology is evident in its robust pipeline of investigational drugs and its ongoing collaborations with other organizations in the healthcare sector. Read More

News & Press Releases

CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio?benzinga.com
Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers.
Via Benzinga · May 18, 2025
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High Growth Momentum and Minervini’s Trend Templatechartmill.com
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.
Via Chartmill · May 17, 2025
9 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 16, 2025
Price Over Earnings Overview: Exelixisbenzinga.com
Via Benzinga · May 16, 2025
Exploring Exelixis's Earnings Expectationsbenzinga.com
Via Benzinga · May 12, 2025
Is the Market Bullish or Bearish on Exelixis?benzinga.com
Via Benzinga · April 29, 2025
Demystifying Exelixis: Insights From 8 Analyst Reviewsbenzinga.com
Via Benzinga · May 15, 2025
Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beatbenzinga.com
Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market.
Via Benzinga · May 14, 2025
Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?benzinga.com
Nasdaq 100 rises further as Nvidia and AMD rally on Middle East investment hopes, while gold tumbles and Treasury yields surge.
Via Benzinga · May 14, 2025
Why Exelixis Stock Is Skyrocketing Todayfool.com
Via The Motley Fool · May 14, 2025
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidancebenzinga.com
Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.
Via Benzinga · May 14, 2025
Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit Expectationsinvestors.com
The top-notch biotech company easily beat first-quarter profit expectations.
Via Investor's Business Daily · May 13, 2025
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
By Exelixis, Inc. · Via Business Wire · May 13, 2025
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May:
By Exelixis, Inc. · Via Business Wire · May 7, 2025
Earnings Scheduled For May 13, 2025benzinga.com
Via Benzinga · May 13, 2025
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidatechartmill.com
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate
Via Chartmill · May 1, 2025
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
By Exelixis, Inc. · Via Business Wire · April 29, 2025
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.chartmill.com
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · April 28, 2025
Does EXELIXIS INC (NASDAQ:EXEL) align with Mark Minervini’s trading strategy?chartmill.com
A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
Via Chartmill · April 25, 2025
Expert Outlook: Exelixis Through The Eyes Of 19 Analystsbenzinga.com
Via Benzinga · April 17, 2025
Why EXELIXIS INC (NASDAQ:EXEL) is Poised for High Growth.chartmill.com
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL).
Via Chartmill · April 16, 2025
EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock and is consolidating.chartmill.com
Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout.
Via Chartmill · April 14, 2025
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.chartmill.com
EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing.
Via Chartmill · April 5, 2025
EXELIXIS INC (NASDAQ:EXEL) stands out as a stock that provides good value for the fundamentals it showcases.chartmill.com
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.
Via Chartmill · April 3, 2025
The Smartest Biotech Stocks to Buy With $50fool.com
Via The Motley Fool · April 3, 2025